Federal News

Displaying results 1-10 (of 64)
 |<  < 1 2 3 4 5 6 7  >  >| 

CSRO Presents at the Patient and Health Advocacy Bio Summit

Dr. Madelaine Feldman traveled to Washington D.C. recently to attend the Patient and Health Advocacy Bio Summit.

READ MORE

CSRO Submits Comments to CMS on Proposed Revisions for 2018

As patient and physician advocates, the CSRO actively monitors regulatory changes that affect physician’s ability to effectively treat their patients and operate their practices. As such, the CSRO took note of and discussed revisions proposed by the Center for Medicare and Medicaid Services for 2018.

READ MORE

Escalating Cost of Prescription Drugs Facilitated by Lack of Transparency

The expansive list of actors involved in delivering prescription drugs to patients substantially inhibits patients from making fully informed treatment and purchasing decisions.

READ MORE

Patient Rights Report Fingers Insurer Practices as Impediment to Patient Access

The Doctor-Patient Rights Project recently released a new study concerning barriers to healthcare access for patients. Titled: Not What the Doctor Ordered, the report focuses on how intrusions by insurers in the patient –physician relationship have forced many patients to forgo the treatments they need.

READ MORE

CSRO Submits Comments in Response to 2018 QPP Proposed Rule

The Coalition of State Rheumatology Organizations (CSRO) and several state societies submitted comments to CMS today in response to the CY 2018 Updates to the Quality Payment Program.

READ MORE

Lawsuits Target Pharmacies Over Prescription Drug Costs

As patients, providers, and politicians alike look for answers to the soaring cost of prescription drugs, some patients have taken matters into their own hands. A series of lawsuits have popped up across the country targeting pharmacies and their relationship to pharmacy benefit managers.

READ MORE

FDA Creates Pathway for Interchangeable Biologics

The FDA has released its highly anticipated but long delayed interchangeability guidelines, and the market seems primed for new developments.

READ MORE

AMA House of Delegates Policy Update

At the AMA’s Annual House of Delegate Meeting, hundreds of medical professionals gathered to discuss and address a wide range of healthcare issues, including the opioid crisis, physician burnout, regulating physician assistants and advanced practice registered nurses, and of course, healthcare reform and drug pricing.

READ MORE

States move to enforce FDA’s Biosimilar Interchangeability Guidelines from the Ground Up

The Food and Drug Administration’s guidelines for biosimilar interchangeability, released in January 2017, have come under renewed focus with concerns about patients being switched onto biosimilars by insurers without consultation with their physicians.

READ MORE

Senate HELP Committee Wades into Drug Prices Debate

Despite intractable differences between the parties on healthcare policy, the Senate’s Health, Education, Labor, and Pensions Committee (HELP) convened a hearing this week to frame future efforts in combating high drug prices.

READ MORE

Displaying results 1-10 (of 64)
 |<  < 1 2 3 4 5 6 7  >  >|